LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

LLY

1,042.36

-1.13%↓

JNJ

210.54

+0.48%↑

ABBV

224.13

+0.08%↑

UNH

331.16

-0.89%↓

AZN

89.91

-1.6%↓

Strona główna・Stock List・Fate Therapeutics Inc

Fate Therapeutics Inc

Closed

SectorHealthcare

1.05 -3.67

Buy Sell

Overview

Share price change

24h

Current

Min

1.04

Max

1.12

Key metrics
By Trading Economics
Income	1.8M -32M
Sales	-166K 1.7M
EPS	-0.27
Profit margin	-1,852.384
Employees	181
EBITDA	7.9M -29M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+358.72% upside

Market Stats
By TradingEconomics
Market Cap	3.5M 129M
Previous open	4.72
Previous close	1.05

News Sentiment

By Acuity

26%

74%

71 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

0.9101 / 1.14 Support & Resistance

Fate Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 gru 2025, 23:50 UTC

Hot Stocks

Stocks to Watch: Micron, MillerKnoll, HireQuest, Insmed

17 gru 2025, 23:20 UTC

Earnings

Correction to Micron Logs Sales Jump Article

17 gru 2025, 23:07 UTC

Earnings

Micron Logs Sales Jump, Sees Further Growth as AI Demand Outpaces Supply -- Update

17 gru 2025, 21:37 UTC

Earnings

Micron Technology 1Q Sales Jump 57%, Led By Memory Growth

17 gru 2025, 23:53 UTC

Market Talk

Gold Edges Higher, Supported by Some Tailwinds -- Market Talk

17 gru 2025, 23:43 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Decline -- Market Talk

17 gru 2025, 23:06 UTC

Acquisitions, Mergers, Takeovers

Asahi Group: Transaction Expected to Be Closed in 2H of Calendar Year 2026

17 gru 2025, 23:05 UTC

Acquisitions, Mergers, Takeovers

Asahi Group: Currently No Plans of Issuing New Shares in Asahi

17 gru 2025, 23:04 UTC

Acquisitions, Mergers, Takeovers

Asahi Group: Funds to Be Provided Via Borrowings From Financial Institutions or Cash on Hand

17 gru 2025, 23:03 UTC

Acquisitions, Mergers, Takeovers

Asahi Group: Acquisition of 53.68% Stake in UDV (Kenya) is $646M on Equity Value Basis

17 gru 2025, 23:02 UTC

Acquisitions, Mergers, Takeovers

Asahi Group: Acquisition of 100% Stake in Diageo Kenya is $2.354B on Equity Value Basis

17 gru 2025, 22:59 UTC

Acquisitions, Mergers, Takeovers

Asahi Group: Deal Part of Strategy Under Medium- to Long-Term Management Policy

17 gru 2025, 22:57 UTC

Acquisitions, Mergers, Takeovers

Asahi Group: To Indirectly Acquire 65.00% Stake in East African Breweries PLC

17 gru 2025, 22:56 UTC

Acquisitions, Mergers, Takeovers

Asahi Group: Stakes Acquired From Two Subsidiaries of Diageo Plc

17 gru 2025, 22:55 UTC

Acquisitions, Mergers, Takeovers

Asahi Group Holdings: To Acquire 100% Stake in Diageo Kenya Ltd., 53.68% Stake in UVD (Kenya) Ltd.

17 gru 2025, 22:49 UTC

Market Talk

Sandfire Resources Production Pipeline Strength Questioned -- Market Talk

17 gru 2025, 21:58 UTC

Earnings

Micron Crushes Earnings. The Stock Is Rising. -- Barrons.com

17 gru 2025, 21:50 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Tech, Media & Telecom Roundup: Market Talk

17 gru 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 gru 2025, 21:46 UTC

Earnings

Salesforce and Other AI Stocks That Can Catch Up to the Pack -- Barrons.com

17 gru 2025, 21:20 UTC

Earnings

Micron Crushes Earnings. The Stock Is Rising. -- Barrons.com

17 gru 2025, 21:10 UTC

Earnings

Micron Beats Earnings. The Stock Is Rising. -- Barrons.com

17 gru 2025, 21:05 UTC

Earnings

Micron Technology Anticipates Business Performance to Continue Strengthening Through FY26

17 gru 2025, 21:04 UTC

Earnings

Micron Technology: 2Q Outlook Reflects Substantial Records Across Rev, Gross Margin, EPS and Free Cash Flow >MU

17 gru 2025, 21:04 UTC

Earnings

Micron Technology Sees 2Q Oper Expenses $1.56B, Plus or Minus $20M >MU

17 gru 2025, 21:03 UTC

Earnings

Micron Technology Sees 2Q Adj EPS $8.42, Plus or Minus 20c >MU

17 gru 2025, 21:03 UTC

Earnings

Micron Technology Sees 2Q EPS $8.19, Plus or Minus 20c >MU

17 gru 2025, 21:03 UTC

Earnings

Micron Technology Sees 2Q Revenue $18.7B, Plus or Minus $400M >MU

17 gru 2025, 21:02 UTC

Earnings

Micron Technology 1Q Operating Cash Flow $8.41 B >MU

17 gru 2025, 21:01 UTC

Earnings

Micron Technology 1Q Rev $13.64B >MU

Peer Comparison

Price change

Fate Therapeutics Inc Forecast

Price Target

By TipRanks

358.72% upside

12 Months Forecast

Average 5 USD 358.72%

High 8 USD

Low 2 USD

Based on 8 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

8 ratings

Buy

Hold

Sell

Based on 8 analysts giving stock ratings to Fate Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.9101 / 1.14Support & Resistance

Recent bearish events outweigh bullish events.

All events are bullish.

There are no events.

Sentiment

By Acuity

71 / 374 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.